• antipsychotic agents;
  • olanzapine;
  • prevention;
  • risk factors;
  • venous thromboembolism

Aims:  Psychiatric disorders and treatment with conventional antipsychotic medications have been associated with venous thromboembolism, but only a few data on recent antipsychotics such as olanzapine are available.

Methods:  We describe four subjects treated with olanzapine who developed venous thromboembolism, and were hospitalized at the University Hospital in Hradec Kralove during the period 2004–2006.

Results:  We found a combination of several clinical and laboratory risk factors in our patients.

Conclusions:  A cohort study or case–control studies are needed to better elucidate the possible role of olanzapine in etiopathogenesis of venous thromboembolism.